MAPT and Alzheimer disease: A sporadic AD rat model which was developed by intracerebral administration of streptozotocin (STZ) revealed increased AD characteristics including, p-tau, Aβ42, and neuroinflammation, and impaired IGF-1R/Akt signaling.